497 related articles for article (PubMed ID: 29378611)
1. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
[TBL] [Abstract][Full Text] [Related]
2. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
[TBL] [Abstract][Full Text] [Related]
3. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
Massanella M; Esteve A; Buzón MJ; Llibre JM; Puertas MC; Gatell JM; Domingo P; Stevenson M; Clotet B; Martinez-Picado J; Blanco J;
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):152-60. PubMed ID: 23392458
[TBL] [Abstract][Full Text] [Related]
5. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK;
J Virol; 2014 Mar; 88(6):3516-26. PubMed ID: 24403590
[TBL] [Abstract][Full Text] [Related]
6. Modelling HIV-1 2-LTR dynamics following raltegravir intensification.
Luo R; Cardozo EF; Piovoso MJ; Wu H; Buzon MJ; Martinez-Picado J; Zurakowski R
J R Soc Interface; 2013 Jul; 10(84):20130186. PubMed ID: 23658114
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication.
Pierson TC; Kieffer TL; Ruff CT; Buck C; Gange SJ; Siliciano RF
J Virol; 2002 Apr; 76(8):4138-44. PubMed ID: 11907256
[TBL] [Abstract][Full Text] [Related]
8. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
Puertas MC; Gómez-Mora E; Santos JR; Moltó J; Urrea V; Morón-López S; Hernández-Rodríguez A; Marfil S; Martínez-Bonet M; Matas L; Muñoz-Fernández MA; Clotet B; Blanco J; Martinez-Picado J
J Antimicrob Chemother; 2018 Jul; 73(7):1940-1948. PubMed ID: 29635527
[TBL] [Abstract][Full Text] [Related]
9. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
10. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
[TBL] [Abstract][Full Text] [Related]
11. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
Hatano H; Strain MC; Scherzer R; Bacchetti P; Wentworth D; Hoh R; Martin JN; McCune JM; Neaton JD; Tracy RP; Hsue PY; Richman DD; Deeks SG
J Infect Dis; 2013 Nov; 208(9):1436-42. PubMed ID: 23975885
[TBL] [Abstract][Full Text] [Related]
12. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
[TBL] [Abstract][Full Text] [Related]
13. A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication.
Orlandi C; Canovari B; Bozzano F; Marras F; Pasquini Z; Barchiesi F; De Maria A; Magnani M; Casabianca A
J Transl Med; 2020 May; 18(1):204. PubMed ID: 32429953
[TBL] [Abstract][Full Text] [Related]
14. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
15. [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
Llibre JM; Martínez-Picado J
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():17-22. PubMed ID: 19572421
[TBL] [Abstract][Full Text] [Related]
16. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Buzón MJ; Massanella M; Llibre JM; Esteve A; Dahl V; Puertas MC; Gatell JM; Domingo P; Paredes R; Sharkey M; Palmer S; Stevenson M; Clotet B; Blanco J; Martinez-Picado J
Nat Med; 2010 Apr; 16(4):460-5. PubMed ID: 20228817
[TBL] [Abstract][Full Text] [Related]
18. Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
Buzón MJ; Codoñer FM; Frost SD; Pou C; Puertas MC; Massanella M; Dalmau J; Llibre JM; Stevenson M; Blanco J; Clotet B; Paredes R; Martinez-Picado J
PLoS Pathog; 2011 Oct; 7(10):e1002314. PubMed ID: 22046128
[TBL] [Abstract][Full Text] [Related]
19. Laboratory surrogate markers of residual HIV replication among distinct groups of individuals under antiretroviral therapy.
Giron LB; Tenore SB; Janini LMR; Sucupira MCA; Diaz RS
PLoS One; 2019; 14(6):e0217502. PubMed ID: 31206536
[TBL] [Abstract][Full Text] [Related]
20. Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.
Bonczkowski P; De Scheerder MA; Malatinkova E; Borch A; Melkova Z; Koenig R; De Spiegelaere W; Vandekerckhove L
Sci Rep; 2016 Dec; 6():38329. PubMed ID: 27910923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
